疫苗研究
ENGLISH ABSTRACT
自制磷酸铝佐剂稳定性研究
杜娇
洪文浩
许哲
姚钰
刘倩
冯潇
杨英英
周海飞
作者及单位信息
·
DOI: 10.3760/cma.j.cn311962-20240717-00050
Stability study of self-made aluminum phosphate adjuvant
Du Jiao
Hong Wenhao
Xu Zhe
Yao Yu
Liu Qian
Feng Xiao
Yang Yingying
Zhou Haifei
Authors Info & Affiliations
Du Jiao
The Forth Bacterial Vaccine Department,Lanzhou Institute of Biological Products Co.,Ltd.,Gansu Provincial Vaccine Technology Innovation Center,Lanzhou 730046,China
Hong Wenhao
The Forth Bacterial Vaccine Department,Lanzhou Institute of Biological Products Co.,Ltd.,Gansu Provincial Vaccine Technology Innovation Center,Lanzhou 730046,China
Xu Zhe
The Forth Bacterial Vaccine Department,Lanzhou Institute of Biological Products Co.,Ltd.,Gansu Provincial Vaccine Technology Innovation Center,Lanzhou 730046,China
Yao Yu
The Forth Bacterial Vaccine Department,Lanzhou Institute of Biological Products Co.,Ltd.,Gansu Provincial Vaccine Technology Innovation Center,Lanzhou 730046,China
Liu Qian
The Forth Bacterial Vaccine Department,Lanzhou Institute of Biological Products Co.,Ltd.,Gansu Provincial Vaccine Technology Innovation Center,Lanzhou 730046,China
Feng Xiao
The Forth Bacterial Vaccine Department,Lanzhou Institute of Biological Products Co.,Ltd.,Gansu Provincial Vaccine Technology Innovation Center,Lanzhou 730046,China
Yang Yingying
The Forth Bacterial Vaccine Department,Lanzhou Institute of Biological Products Co.,Ltd.,Gansu Provincial Vaccine Technology Innovation Center,Lanzhou 730046,China
Zhou Haifei
The Forth Bacterial Vaccine Department,Lanzhou Institute of Biological Products Co.,Ltd.,Gansu Provincial Vaccine Technology Innovation Center,Lanzhou 730046,China
·
DOI: 10.3760/cma.j.cn311962-20240717-00050
0
0
0
0
0
0
PDF下载
APP内阅读
摘要

目的评价自制磷酸铝佐剂在不同储存条件下的稳定性,为该佐剂的储存和有效期设置提供数据支持。

方法选取连续3批产业化规模的自制磷酸铝佐剂,分别置于(5±3)℃和(25±2)℃储存。定期取样考察磷酸铝佐剂的主要评价指标(外观、pH值、铝含量、吸附率、氯化钠含量、沉降上清分析、无菌性、细菌内毒素、砷盐、铁盐、硫酸盐、铵盐、重金属、磷铝摩尔比、零电荷点、粒径大小与分布)。

结果3批磷酸铝佐剂在2种温度下储存15个月后,外观、无菌性均合格,pH值在5.4~6.2之间,吸附率在93%~100%之间,铝含量在2.77~3.36 mg/mL之间,氯化钠含量在7.90~8.60 g/L之间,沉降上清分析在12~15 mL之间,细菌内毒素在0.5~3.0 内毒素单位/mg铝之间,磷铝摩尔比在0.82~1.13之间,累积分布达到10%、50%、90%时对应的粒径大小分别为1.75~2.53、2.87~3.98和4.94~6.90 μm,零电荷点在5.11~5.47之间,残留杂质砷盐≤0.001‰、铁盐≤0.015‰、硫酸盐≤0.5%、铵盐≤0.005%、重金属≤0.002%,佐剂各项主要评价指标均稳定且符合质量标准。

结论3批自制磷酸铝佐剂在(5±3)℃和(25±2)℃条件下保存15个月后稳定性良好,为磷酸铝佐剂储存条件及效期的制定提供了依据。

佐剂,磷酸铝;稳定性;佐剂-抗原作用;磷铝摩尔比;零电荷点
ABSTRACT

ObjectiveTo evaluate the stability of the self-made aluminum phosphate adjuvant under different storage conditions so as to provide supportive data for the storage and expiration date of the adjuvant.

MethodsThree consecutive batches of industrial-scale self-made aluminum phosphate adjuvant were selected and stored at (5±3) ℃ and (25±2) ℃, respectively. The main evaluation indices of aluminum phosphate adjuvant (appearance, pH value, aluminum content, adsorption rate, sodium chloride content, analysis of sedimentation supernatant, sterility, bacterial endotoxin, arsenic salt, iron salt, sulfate salt, ammonium salt, heavy metals, phosphorus to aluminum molar ratio, zero charge point, particle size and distribution) were investigated by sampling at regular intervals.

ResultsThe appearance and sterility of 3 batches of aluminum phosphate adjuvant were qualified after stored at two temperatures for 15 months. The pH value was 5.4-6.2, the adsorption rate was 93%-100%, the aluminum content was 2.77-3.36 mg/mL, the sodium chloride content was 7.90-8.60 g/L, and the sedimentation supernatant analysis ranged from 12 to 15 mL .The bacterial endotoxin ranged from 0.5 to 3.0 endotoxin unit/mg aluminum, and the molar ratio of phosphorus to aluminum ranged from 0.82 to 1.13. The particle size corresponding to the cumulative distribution reaching 10%, 50% and 90% were 1.75-2.53, 2.87-3.98 and 4.94-6.90 μm, respectively. The zero charge point was 5.11-5.47, with the residual impurity of arsenic salt ≤0.001‰, iron salt ≤0.015‰, sulfate salt ≤0.5%, ammonium salt ≤0.005% and heavy metal ≤0.002%. All main evaluation indices of the adjuvant were stable and in line with the quality standard.

ConclusionThree batches of self-made aluminum phosphate adjuvant show good stability after being stored at (5±3) ℃ and (25±2) ℃ for 15 months, which provides a basis for the formulation of storage conditions and efficacy of aluminum phosphate adjuvant.

Adjuvant,aluminum phosphate;Stability;Adjuvant-antigen interaction;Molar ratio of phosphorus-aluminum;Zero charge point
Zhou Haifei, Email: mocdef.3ab61wohciefiah
引用本文

杜娇,洪文浩,许哲,等. 自制磷酸铝佐剂稳定性研究[J]. 国际生物制品学杂志,2025,48(01):10-15.

DOI:10.3760/cma.j.cn311962-20240717-00050

PERMISSIONS

Request permissions for this article from CCC.

评价本文
*以上评分为匿名评价
佐剂是疫苗产品组成的一部分,佐剂的加入不仅有助于增强疫苗稳定性,还能增强其有效性。铝佐剂是人用疫苗中使用最广泛的无机佐剂,在减少抗原用量和接种次数、提高疫苗免疫持久性等方面显示出独特的优势 1。疫苗中常用的铝佐剂主要为氢氧化铝佐剂和磷酸铝佐剂。目前,磷酸铝佐剂已在如吸附白喉/破伤风类毒素疫苗、脑膜炎双球菌B疫苗Trumenba ®、13价肺炎球菌多糖结合疫苗Prevnar 13 ®、20价肺炎球菌多糖结合疫苗Prevnar 20 ®等疫苗中应用 2。然而,铝佐剂的稳定性和有效性很大程度上会限制疫苗制剂的稳定性和免疫功效 3 , 4,需要对铝佐剂进行稳定性研究,科学制定其保存温度和效期。
本研究依据《新原料药和制剂的稳定性试验》Q1A(R2) 5、《预防用含铝佐剂疫苗技术指导原则》等 6 , 7 , 8,对兰州生物制品研究所有限责任公司(兰州公司)生产的3批产业化规模磷酸铝佐剂(自制磷酸铝佐剂)进行稳定性研究,动态观察其外观、pH值、吸附率、铝含量、氯化钠含量、沉降上清分析、无菌性、细菌内毒素、砷盐、铁盐、重金属、硫酸盐、铵盐、磷铝摩尔比(P/Al)、零电荷点、粒径大小与分布等主要质控指标,评估其稳定性,为磷酸铝佐剂的储存条件及效期的制定提供依据。
试读结束,您可以通过登录机构账户或个人账户后获取全文阅读权限。
参考文献
[1]
Shi S Zhu H Xia X et al. Vaccine adjuvants:understanding the structure and mechanism of adjuvanticity[J]. Vaccine 20193724):3167-3178. DOI: 10.1016/j.vaccine.2019.04.055 .
返回引文位置Google Scholar
百度学术
万方数据
[2]
Zhang T He P Guo D et al. Research progress of aluminum phosphate adjuvants and their action mechanisms[J]. Pharmaceutics 2023156):1756. DOI: 10.3390/pharmaceutics15061756 .
返回引文位置Google Scholar
百度学术
万方数据
[3]
Xu K Wang Z Qin M et al. A systematic review and meta-analysis of the effectiveness and safety of COVID-19 vaccination in older adults[J]. Front Immunol 2023141113156. DOI: 10.3389/FIMMU.2023.1113156 .
返回引文位置Google Scholar
百度学术
万方数据
[4]
Smith WJ Thompson R Egan PM et al. Impact of aluminum adjuvants on the stability of pneumococcal polysaccharide-protein conjugate vaccines[J]. Vaccine 20234135):5113-5125. DOI: 10.1016/j.vaccine.2023.05.059 .
返回引文位置Google Scholar
百度学术
万方数据
[5]
Harmonised Tripartite Guideline ICH . Stability testing of new drug substances and products Q1A(R2)[EB/OL].( 2003-02-06)[2024-05-10]. https://database.ich.org/sites/default/files/Q1A%28R2%29%20Guideline.
返回引文位置Google Scholar
百度学术
万方数据
[6]
国家药品监督管理局. 预防用含铝佐剂疫苗技术指导原则[EB/OL].( 2019-12-09)[2024-05-10]. https://www.nmpa.gov.cn/xxgk/ggtg/ypggtg/ypqtggtg/20191212145901474.html.
返回引文位置Google Scholar
百度学术
万方数据
[7]
金苏姚昕陈庆华. 预防性疫苗铝佐剂的药学相关问题及初步考虑[J]. 中国生物制品学杂志 2020335):603-607. DOI: 10.13200/j.cnki.cjb.003066 .
返回引文位置Google Scholar
百度学术
万方数据
[8]
Burrell LS White JL Hem SL . Stability of aluminium-containing adjuvants during aging at room temperature[J]. Vaccine 20001821):2188-2192. DOI: 10.1016/S0264-410X(00)00031-1 .
返回引文位置Google Scholar
百度学术
万方数据
[9]
国家药典委员会中华人民共和国药典2020年版四部[M]. 北京中国医药科技出版社 2020156-160,178-181,287-288,370-372,535-536.
[10]
周萌萌江凡黄莺. 药品稳定性研究相关要求及常见缺陷分析[J]. 中国药事 20233711):1282-1289. DOI: 10.16153/j.1002-7777.2023.11.008 .
返回引文位置Google Scholar
百度学术
万方数据
[11]
Mei C Deshmukh S Cronin J et al. Aluminum phosphate vaccine adjuvant:analysis of composition and size using off-line and in-line tools[J]. Comput Struct Biotechnol J 2019171184-1194. DOI: 10.1016/J.CSBJ.2019.08.003 .
返回引文位置Google Scholar
百度学术
万方数据
[12]
Burrell LS Johnston CT Schulze D et al. Aluminium phosphate adjuvants prepared by precipitation at constant pH. Part Ⅱ:Physicochemical properties[J]. Vaccine 2000192/3):282-287. DOI: 10.1016/s0264-410x(00)00162-6 .
返回引文位置Google Scholar
百度学术
万方数据
[13]
Klein J Ushio M Burrell LS et al. Analysis of aluminum hydroxyphosphate vaccine adjuvants by(27)Al MAS NMR[J]. J Pharm Sci 2000893):311-321. DOI: 10.1002/(SICI)1520-6017(200003)89:3<311::AID-JPS3>3.0.CO;2-8
返回引文位置Google Scholar
百度学术
万方数据
[14]
Hem SL Hogenesch H . Relationship between physical and chemical properties of aluminum-containing adjuvants and immunopotentiation[J]. Expert Rev Vaccines 200765):685-698. DOI: 10.1586/14760584.6.5.685 .
返回引文位置Google Scholar
百度学术
万方数据
[15]
王晓娟马锐曹琰. 铝佐剂及佐剂吸附疫苗质量标准的探讨[J]. 中国生物制品学杂志 2019324):485-488. DOI: 10.13200/j.cnki.cjb.002572 .
返回引文位置Google Scholar
百度学术
万方数据
备注信息
A
周海飞,Email: mocdef.3ab61wohciefiah
B

杜娇:实验设计、研究实施、论文撰写、数据分析;洪文浩、许哲:研究实施、数据分析;姚钰:数据分析;刘倩、冯潇、杨英英:数据采集;周海飞:实验设计、研究指导、论文修改

C
所有作者均声明不存在利益冲突
D
国家科技重大专项重大新药创制 (2018ZX09738-006)
评论 (0条)
注册
登录
时间排序
暂无评论,发表第一条评论抢沙发
MedAI助手(体验版)
文档即答
智问智答
机器翻译
回答内容由人工智能生成,我社无法保证其准确性和完整性,该生成内容不代表我们的态度或观点,仅供参考。
生成快照
文献快照

你好,我可以帮助您更好的了解本文,请向我提问您关注的问题。

0/2000

《中华医学会杂志社用户协议》 | 《隐私政策》

《SparkDesk 用户协议》 | 《SparkDesk 隐私政策》

网信算备340104764864601230055号 | 网信算备340104726288401230013号

技术支持:

历史对话
本文全部
还没有聊天记录
设置
模式
纯净模式沉浸模式
字号